MedAdvisor (ASX:MDR) - CEO, Robert Read
CEO, Robert Read
Source: Startup Daily
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • MedAdvisor (MDR) has adjusted the price for its capital raise
  • Investors will now be able to grab the health stock’s shares at 38 cents, which is 7 cents cheaper than the initial price
  • The company is aiming to raise $45 million to purchase U.S. based Adheris Health, accelerate its MedAdvisor’s United States’ presence
  • Company shares last traded for 40 cents on October 30

MedAdvisor (MDR) has adjusted the price for its capital raise ahead of its acquisition of U.S.-based Adheris Health.

The company has announced it will change the share price of its capital raise to 38 cents from the previously announced 45 cents-per-share.

This week, MedAdvisor has seen overwhelmingly support from investors since announcing it entered a binding agreement with Syneos Health to purchase Adheris for US$34.5 million (approximately A$47 million).

“Whilst there was strong support at a price premium on MedAdvisor’s last close to 45 cents, including the company’s largest shareholder HMS, it became clear through the engagement process this week that there was stronger support at a 5 per cent discount to the company’s last close of 40 cents,” the company explained.

Under the capital raise, the company is aiming to raise $45 million, with a minimum target of $35 million.

The purchase will accelerate MedAdvisor’s U.S. presence by using Adheris’ existing pharmacy integrations, reducing the need for MedAdvisor to partner with U.S. pharmacies.

MedAdvisor’s and Adheris technology will integrate to create programs that can positively influence patient behaviour from point of initial prescribing to the pharmacy and when at home.

Company shares last traded for 40 cents on October 30.

MDR by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…